跳至主要内容
临床试验/EUCTR2017-002241-30-FI
EUCTR2017-002241-30-FI进行中(未招募)1 期

A phase IIa, double-blind, randomised, placebo-controlled, dose-finding study on the efficacy and tolerability of a 6-week treatment with ZED1227 capsules vs. placebo in subjects with well-controlled celiac disease undergoing gluten challenge - ZED1227 capsules vs. placebo in celiac disease

Dr. Falk Pharma GmbH0 个研究点目标入组 160 人开始时间: 2017年12月29日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
160

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • Documented initial biopsy proven diagnosis of celiac disease at least 12 months prior to screening,
  • Human leukocyte antigen DQ (HLA-DQ) typing compatible with celiac disease
  • Negative TG2-IgA serology
  • Successful adherence to a gluten-free diet for at least 12 months
  • Negative diagnosis of Helicobacter pylori infection
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 160
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Selective immunoglobulin A deficiency,
  • IgE-specific antibodies against wheat or gliadin,
  • Refractory celiac disease defined as persistent or recurrent malabsorptive symptoms and signs
  • Severe complications of celiac disease
  • Any concomitant diseases of the intestinal tract in addition to celiac disease
  • Diabetes mellitus type 1
  • Evidence of relevant systemic disease

研究者

相似试验